Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it has completed the planned patient enrollment in its U.S. Phase I clinical trial evaluating bavituximab as monotherapy in patients with advanced refractory cancers. In a presentation of preliminary data from this trial at the 2009 ASCO Annual Meeting last month, the study's principal investigator at MD Anderson Cancer Center reported that bavituximab was generally safe and well-tolerated, with a predictable pharmacokinetic profile. In these patients, a maximum tolerated dose had not been reached even at the highest planned dose level. Peregrine has now begun designing additional bavituximab cancer trials based on findings from...

Want to see the full article?

• Purchase this article for only $3.00